189 related articles for article (PubMed ID: 11583069)
21. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
Zema MJ
J Am Coll Cardiol; 2000 Mar; 35(3):640-6. PubMed ID: 10716466
[TBL] [Abstract][Full Text] [Related]
22. Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
Robins SJ; Collins D; McNamara JR; Bloomfield HE
Atherosclerosis; 2008 Feb; 196(2):849-55. PubMed ID: 17335828
[TBL] [Abstract][Full Text] [Related]
23. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
24. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
[TBL] [Abstract][Full Text] [Related]
25. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Sprecher DL
Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
[TBL] [Abstract][Full Text] [Related]
26. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
27. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
[TBL] [Abstract][Full Text] [Related]
28. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment.
Kolovou GD; Cokkinos DV
Curr Med Res Opin; 2002; 18(5):265-8. PubMed ID: 12240788
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
[TBL] [Abstract][Full Text] [Related]
30. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D
Am J Cardiol; 1996 Sep; 78(5):572-5. PubMed ID: 8806347
[TBL] [Abstract][Full Text] [Related]
31. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
Spencer CM; Barradell LB
Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
[TBL] [Abstract][Full Text] [Related]
32. [VA-HIT Study [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study]].
Noto H; Kinoshita M
Nihon Rinsho; 2001 Mar; 59 Suppl 3():442-7. PubMed ID: 11347111
[No Abstract] [Full Text] [Related]
33. The Helsinki Heart Study: basic design and randomization procedure.
Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
[TBL] [Abstract][Full Text] [Related]
34. The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
Krakoff J; Vela BS; Brinton EA
Curr Cardiol Rep; 2000 Sep; 2(5):452-8. PubMed ID: 10980914
[TBL] [Abstract][Full Text] [Related]
35. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
[TBL] [Abstract][Full Text] [Related]
36. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
[TBL] [Abstract][Full Text] [Related]
37. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
[TBL] [Abstract][Full Text] [Related]
38. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Bloomfield Rubins H; Davenport J; Babikian V; Brass LM; Collins D; Wexler L; Wagner S; Papademetriou V; Rutan G; Robins SJ;
Circulation; 2001 Jun; 103(23):2828-33. PubMed ID: 11401940
[TBL] [Abstract][Full Text] [Related]
39. HDL in atherosclerosis: actor or bystander?
Asztalos BF; Schaefer EJ
Atheroscler Suppl; 2003 Mar; 4(1):21-9. PubMed ID: 12714034
[TBL] [Abstract][Full Text] [Related]
40. Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
Lacko AG; Kudchodkar BJ; Loney WW; Clearfield MB; Weis S
Clin Chem Lab Med; 1998 Jun; 36(6):389-92. PubMed ID: 9711427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
